NASDAQ$AURA
Aura Biosciences Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2022, and provided clinical development and operational highlights.
Aura Biosciences reported its first quarter 2022 financial results, highlighting ongoing progress of AU-011 and preparations for pivotal trials in choroidal melanoma, a Phase 1 trial in non-muscle invasive bladder cancer, and submission of an IND for choroidal metastases.
- Aura is on track to meet multiple clinical milestones for AU-011 in the second half of 2022, including initiating a pivotal trial in choroidal melanoma.
- The company plans to initiate a Phase 1 trial in non-muscle invasive bladder cancer and submit an IND for choroidal metastases in 2H 2022.
- Preclinical data presented at ARVO highlighted AU-011's anti-tumor activity and potential as a treatment for choroidal metastases.
- Aura had cash, cash equivalents, and marketable securities totaling $133.3 million as of March 31, 2022, expected to fund operations into 2024.
Headline financials
Revenue & EPS history
Aura Biosciences · Revenue · Quarterly
$600K
Forward guidance
Aura Biosciences is focused on advancing the AU-011 development program and meeting clinical milestones in the second half of 2022.
Tailwinds
- On track to finalize a decision on the route of administration and initiate the pivotal program for AU-011 in choroidal melanoma before the end of the year.
- Building the ocular oncology franchise with choroidal metastases as the second potential ocular indication.
- Abstract highlighting AU-011’s efficacy as a single agent and as a combination therapy with checkpoint inhibitors has been selected for publication at the upcoming 2022 ASCO Annual Meeting.
- Initiating a Phase 1 trial in non-muscle invasive bladder cancer, with multiple clinical sites in the US.
- Investigating additional potential indications for AU-011.
Headwinds
- Uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials.
- The risk that the results of Aura’s clinical trials may not be predictive of future results in connection with future clinical trials.
- Whether Aura will receive regulatory approvals to conduct trials or to market products.
- Whether Aura’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements.
- Risks, assumptions and uncertainties regarding the impact of the continuing COVID-19 pandemic on Aura’s business, operations, strategy, goals and anticipated timelines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q1 2022
+1.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-7.0%
Avg return
30 days after
44%
8 / 18 earnings
Positive
+26.0%
Q3 2021
Best reaction
-8.9%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.1% | -5.5% | -24.3% | |
| Q3 2025 | -0.7% | -2.9% | +17.4% | |
| Q2 2025 | +4.2% | -3.6% | -11.0% | |
| Q1 2025 | +1.9% | -0.5% | +6.8% | |
| Q4 2024 | -6.7% | -15.5% | -23.2% | |
| Q3 2024 | -7.3% | -15.0% | -24.2% | |
| Q1 2024 | -1.1% | +1.9% | +1.6% | |
| Q4 2023 | +2.9% | +1.7% | -5.4% | |
| Q3 2023 | +4.5% | +8.6% | +18.9% | |
| Q2 2023 | -8.9% | -8.8% | -16.4% | |
| Q1 2023 | +0.5% | +7.3% | +22.4% | |
| Q4 2022 | -1.0% | -1.0% | -15.6% | |
| Q3 2022 | +10.1% | +16.4% | +4.4% | |
| Q2 2022 | -0.5% | -2.6% | -19.0% | |
| Q1 2022 | +4.9% | +8.1% | -4.5% | |
| Q2 2021 | -1.5% | +8.7% | -21.4% | |
| Q4 2021 | -1.5% | +8.7% | -21.4% | |
| Q3 2021 | +26.0% | -1.1% | -10.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro